Inactive SLE (n = 50) | Active SLE (n = 23) | p value§ | |
---|---|---|---|
Age, median (IQR) years | 46 (35–59) | 39 (30–52) | 0.20 |
Female sex (%) | 44 (88) | 21 (91) | 0.68 |
Caucasian, no. (%) | 38 (76) | 18 (78) | 0.83 |
Higher education*, no./total (%) | 20/39 (51) | 10/20 (50) | 0.93 |
Active smoker, no. (%) | 9 (18) | 8 (35) | 0.12 |
Body mass index, median (IQR) | 24 (20–29) | 22 (19–24) | 0.35 |
Use of psychiatric medication£, no. (%) | 9 (18) | 5 (22) | 0.75 |
Disease duration, median (IQR) years | 7 (3–15) | 6 (3–15) | 0.42 |
History of lupus nephritis, no (%) | 19 (38) | 6 (26) | 0.31 |
History of neurolupus, no (%) | 6 (12) | 2 (7) | 0.67 |
SELENA-SLEDAI, median (IQR) score | 2 (0–2) | 6 (4–10) | < 0.001 |
PGA score, median (IQR) score | 0 (0–0) | 1 (1–2) | < 0.001 |
Immunomodulators past month, no. (%) | 44 (88) | 20 (87) | 0.90 |
Antimalarials, no. (%) | 37 (74) | 15 (65) | 0.44 |
Systemic corticosteroids, no. (%) | 26 (52) | 13 (57) | 0.72 |
Immunosuppressants, no. (%) | 25 (50) | 10 (43) | 0.60 |